| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 7, 2026 | Matchpoint Therapeutics Nets $150M in Series B |
WATERTOWN, MA, Matchpoint Therapeutics announced the successful closing of a $150 million Series B financing co-led by Nextech Invest and Norwest.
>> Click here for more funding data on Matchpoint Therapeutics
>> To export Matc... |
| Aug 13, 2026 | Khartis Therapeutics Raises $50M To Advance Oral Immunology Drugs | Khartis Therapeutics Raises $50M Series B
Khartis Therapeutics has raised $50 million in Series B funding to advance its oral medicine pipeline.mForge Life Science Partners led the round. Longwood Fund and Alexandria Venture Investments joi... |
| Jul 9, 2026 | Flare Therapeutics Secures $85M Series C Round |
CAMBRIDGE, MA, Flare Therapeutics, a clinical-stage biotechnology company, announced the closing of an $85 million Series C financing.
>> Click here for more funding data on Flare Therapeutics
>> To export Flare Therapeutics fu... |
| Apr 6, 2026 | Stipple Bio Raises $100M in Series A Financing | Stipple Bio, Inc., a Cambridge, MA-based biotechnology company leveraging epitope-level precision to create targeted cancer therapies, closed a $100m Series A financing.
The round was co-led by RA Capital, a16z Bio+Health and Nextech Invest... |
| Jan 8, 2026 | Parabilis Medicines Raises $305M Series F Funding | Parabilis Medicines, a Cambridge, MA-based clinical-stage biopharmaceutical company committed to creating medicines for people living with cancer, closed a $305m Series F financing.
The round was co-led by RA Capital Management, Fidelity Ma... |
| Dec 28, 2025 | Atavistik Bio Secures $120 Million: Advancing Precision Therapies for HHT and MPNs | Atavistik Bio secured $120 million in Series B funding. This substantial capital will advance two crucial therapeutic programs. An oral AKT1-selective inhibitor targets Hereditary Hemorrhagic Telangiectasia (HHT). A JAK2 V617F mutant-select... |
| Dec 27, 2025 | Atavistik Bio: $120 Million Series B Raised To Advance Selective Allosteric Small-Molecule Programs In HHT And MPNs | Atavistik Bio announced it raised a $120 million Series B financing to push two selective allosteric small-molecule programs into clinical proof-of-concept studies: an oral, AKT1-selective allosteric inhibitor for hereditary hemorrhagic tel... |
| Dec 21, 2025 | Atavistik Bio Raises $120M in Series B Financing | Atavistik Bio, a Cambridge, MA-based developer of selective allosteric small molecule therapeutics, raised $120m in Series B financing.
The round was led by Nextech Invest and The Column Group with participation from Lux Capital and new inv... |
| Nov 3, 2025 | Tubulis: Second Tranche Of €344 Million Series C Closed To Advance ADC Pipeline | Tubulis announced the second and final closing of its Series C financing round, bringing the total raised to €344 million ($401 million). The round included new investors Fidelity Management & Research Company, Janus Henderson Investors... |
| Oct 30, 2025 | Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $ 401M) |
MUNICH, GERMANY, October 30, 2025 – Tubulis today announced a second and final closing of its Series C round totaling €344M (US $401M). The second closing brought in additional new investors Fidelity Management & Research Company, Janu... |
| Oct 23, 2025 | Electra Therapeutics: $183 Million Series C Raised To Advance SIRP-Targeted Therapies For Immune Disorders And Cancer | Electra Therapeutics, a clinical-stage biotechnology company pioneering therapies against novel targets in immunology and cancer, has announced the close of an oversubscribed $183 million Series C financing round. The round was co-led by Ne... |
| Oct 22, 2025 | Electra Therapeutics Raises $183M in Series C Funding | Electra Therapeutics, a South San Francisco, CA-based clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, raised $183m in Series C financing.
The round was co-led by Nextech... |
| Oct 22, 2025 | EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics | EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics
Wed, Oct 22, 2025 13:10 CET Report this content
Electra Therapeutics is a late-stage biotechnology company developing new medicines for people with seriou... |
| Oct 16, 2025 | German biotech Tubulis secures record-breaking €308M Series C | Tubulis, a pioneer in the development of uniquely matched antibody-drug conjugates (ADCs), this week announced the successful closing of a €308 million Series C financing round.
This landmark round marks the largest Series C raised by a Eur... |
| Oct 15, 2025 | Tubulis: €308 Million Series C Secured To Advance Clinical Development Of Lead ADC Candidate TUB-040 | Tubulis announced the closing of a €308 million ($361 million) Series C financing round aimed at accelerating the clinical development of its lead antibody-drug conjugate (ADC) candidate, TUB-040. The round was led by Venrock Healthcare Cap... |
| Oct 15, 2025 | Tubulis Raises €308M In Series C Funding | Tubulis, a Munich, Germany-based oncology company, closed a €308 million (USD 361m) Series C financing.
The round was led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management and Asce... |
| Oct 15, 2025 | Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline | • USD 361 million round represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally
• Round led by Venrock Healthcare Capital Partners with participation from other new... |
| Sep 12, 2024 | Circle Pharma: $90 Million (Series D) Raised For Improving Oral Macrocycle Therapies | Circle Pharma, a clinical-stage biopharmaceutical company focused on discovering and developing cell-permeable macrocycles as a new class of therapies, announced the successful closing of a $90 million Series D financing round – which inclu... |
| Sep 4, 2024 | Circle Pharma Secures $90 Million to Propel Innovative Cancer Therapies | In the bustling heart of South San Francisco, Circle Pharma has struck gold. The clinical-stage biopharmaceutical company recently closed a $90 million Series D financing round. This infusion of capital is not just a financial boost; it’s a... |
| Sep 3, 2024 | Circle Pharma Closes $90M Series D Financing | Circle Pharma, a San Francisco, CA-based clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, raised $90M in Series D funding.
The round was led by The Colu... |
| Aug 13, 2024 | IDRx Raises $120 Million To Transform Cancer Treatment With Precision Therapies | IDRx (a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies) announced the completion of an oversubscribed $120 million Series B Preferred Stock financing. This financin... |
| Jul 29, 2024 | Scorpion Therapeutics: A Bold Leap in Precision Oncology | Scorpion Therapeutics is making waves in the world of cancer treatment. With a recent $150 million Series C funding round, the Boston-based biotech is poised to redefine the landscape of precision oncology. This funding is not just a financ... |
| Jul 27, 2024 | Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline | Scorpion Therapeutics, a clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, announced the closing of a $150 million Series C financing. The funding was co... |
| Aug 2, 2022 | Investing in IDRx | HIV ravaged entire communities before antiretroviral cocktail therapies helped turn the tide. Cocktail therapies combine multiple drugs: Some hit parts of the replication machinery the virus uses to make copies of itself, others block its a... |
| Oct 9, 2017 | Adage Capital Leads $8M Funding for ImaginAb | ImaginAb, an immuno-oncology imaging company, has raised an additional $8 million in new equity funding led by Adage Capital. The company's shareholders also include the Parker Institute for Cancer Immunotherapy, NVF, Cycad Group, Nextech I... |
| Oct 9, 2017 | Adage Capital Leads $8M Funding for ImaginAb | ImaginAb, an immuno-oncology imaging company, has raised an additional $8 million in new equity funding led by Adage Capital. The company's shareholders also include the Parker Institute for Cancer Immunotherapy, NVF, Cycad Group, Nextech I... |
| Jul 21, 2016 | Nextech Invest Closes Oncology Fund IV, at $64M | Nextech Invest Ltd., a Zurich, Switzerland-based specialist oncology private equity investor, closed its fourth fund, at $64m.
Oncology Fund IV, whose Limited Partners are based in the USA, Europe and Asia, will be invested in companies tha... |
| May 11, 2014 | ImaginAb Raises $21M in Series B Funding | ImaginAb, an Inglewood, CA-based clinical stage biotech company, raised $21m in Series B funding.
The round was led by Mérieux Développement, with participation from Novartis Venture Funds, Cycad Group and Nextech Invest.
The company intend... |
| Jan 8, 2014 | Blueprint Medicines Completes $25M Series B Financing | Blueprint Medicines, a Cambridge, MA-based oncology company, completed a $25m Series B financing.
The round was led by Nextech Invest Ltd., with participation from founding investors Third Rock Ventures and Fidelity Biosciences as well as p... |
| Dec 17, 2013 | Rahmenbedingungen für Börsengänge sind derzeit gut | |
| Dec 5, 2013 | Dispute between entrepreneurs and venture capitalists | |
| Dec 17, 2012 | Cancer therapeutic that causes “executioner” protein to kill cancer cells raises $5M | The latest financing follows a $6 million fresh capital raise last year. In October 2010, it raised $32 million in a Series C round.
Among the company’s institutional investors are Clarus Ventures, HealthCare Ventures, Quaker Partners, Novi... |
| Mar 27, 2012 | ImaginAb Completes $12.5M Series A Financing | ImaginAb, Inc., a Los Angeles, CA-based clinical-stage company developing in vivo imaging agents for Positron Emission Tomography (PET) based on antibody fragment technology, completed a $12.5m Series A financing.
The round was led by Novar... |
| Cancer therapeutic that causes “executioner” protein to kill cancer cells raises $5M | A company with a small molecule cancer treatment to combat solid tumor cancers as well as hematological malignancies has raised $5 million in a combination of debt, options and warrants, according to a Form D filing with the Securities and ... |
